DE602004021095D1 - Verfahren zum screening der leichten kette eines antikörpers - Google Patents
Verfahren zum screening der leichten kette eines antikörpersInfo
- Publication number
- DE602004021095D1 DE602004021095D1 DE602004021095T DE602004021095T DE602004021095D1 DE 602004021095 D1 DE602004021095 D1 DE 602004021095D1 DE 602004021095 T DE602004021095 T DE 602004021095T DE 602004021095 T DE602004021095 T DE 602004021095T DE 602004021095 D1 DE602004021095 D1 DE 602004021095D1
- Authority
- DE
- Germany
- Prior art keywords
- antibody
- library
- desired antigen
- screening
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title abstract 3
- 238000012216 screening Methods 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 abstract 5
- 102000036639 antigens Human genes 0.000 abstract 5
- 108091007433 antigens Proteins 0.000 abstract 5
- 230000003248 secreting effect Effects 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pyrane Compounds (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003012648 | 2003-01-21 | ||
PCT/JP2004/000496 WO2004065611A1 (fr) | 2003-01-21 | 2004-01-21 | Procede de selection par criblage d'une chaine legere d'anticorps |
Publications (1)
Publication Number | Publication Date |
---|---|
DE602004021095D1 true DE602004021095D1 (de) | 2009-06-25 |
Family
ID=32767339
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE602004021095T Expired - Lifetime DE602004021095D1 (de) | 2003-01-21 | 2004-01-21 | Verfahren zum screening der leichten kette eines antikörpers |
Country Status (6)
Country | Link |
---|---|
US (1) | US8337841B2 (fr) |
EP (1) | EP1605058B1 (fr) |
JP (1) | JP4477579B2 (fr) |
AT (1) | ATE431423T1 (fr) |
DE (1) | DE602004021095D1 (fr) |
WO (1) | WO2004065611A1 (fr) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003087163A1 (fr) * | 2002-04-15 | 2003-10-23 | Chugai Seiyaku Kabushiki Kaisha | Procede d'elaboration d'une banque scdb |
JP4794301B2 (ja) * | 2003-06-11 | 2011-10-19 | 中外製薬株式会社 | 抗体の製造方法 |
AU2003271174A1 (en) | 2003-10-10 | 2005-04-27 | Chugai Seiyaku Kabushiki Kaisha | Double specific antibodies substituting for functional protein |
JPWO2005035754A1 (ja) * | 2003-10-14 | 2006-12-21 | 中外製薬株式会社 | 機能蛋白質を代替する二種特異性抗体 |
TW200530269A (en) * | 2003-12-12 | 2005-09-16 | Chugai Pharmaceutical Co Ltd | Anti-Mpl antibodies |
JPWO2005056602A1 (ja) * | 2003-12-12 | 2008-03-06 | 中外製薬株式会社 | アゴニスト活性を有する改変抗体のスクリーニング方法 |
EP1710255A4 (fr) * | 2003-12-12 | 2008-09-24 | Chugai Pharmaceutical Co Ltd | Anticorps modifies reconnaissant un recepteur trimere ou plus grand |
TWI671403B (zh) | 2005-03-31 | 2019-09-11 | 中外製藥股份有限公司 | 控制組裝之多肽的製造方法 |
WO2006106903A1 (fr) * | 2005-03-31 | 2006-10-12 | Chugai Seiyaku Kabushiki Kaisha | ISOMERES STRUCTURELS sc(Fv)2 |
SI1876236T1 (sl) * | 2005-04-08 | 2014-11-28 | Chugai Seiyaku Kabushiki Kaisha | Protitelo, ki funkcionalno nadomesti faktor viii za koagulacijo krvi |
TW200718780A (en) * | 2005-06-10 | 2007-05-16 | Chugai Pharmaceutical Co Ltd | Sc(Fv)2 site-directed mutant |
AU2006256041B2 (en) * | 2005-06-10 | 2012-03-29 | Chugai Seiyaku Kabushiki Kaisha | Stabilizer for protein preparation comprising meglumine and use thereof |
US9241994B2 (en) | 2005-06-10 | 2016-01-26 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical compositions containing sc(Fv)2 |
CA2625222A1 (fr) * | 2005-10-11 | 2007-04-19 | Domantis Limited | Criblage de bibliotheques de polypeptides d'anticorps et polypeptides d'anticorps selectionnes |
WO2007114325A1 (fr) | 2006-03-31 | 2007-10-11 | Chugai Seiyaku Kabushiki Kaisha | Procédé de modification d'anticorps pour purifier un anticorps bispécifique |
US11046784B2 (en) | 2006-03-31 | 2021-06-29 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
MX369784B (es) | 2007-09-26 | 2019-11-21 | Chugai Pharmaceutical Co Ltd | Metodo de modificacion del punto isoelectrico de anticuerpos mediante la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr). |
ES2413379T3 (es) | 2008-08-28 | 2013-07-16 | Novartis Ag | Presentación en la superficie celular de isoformas polipeptídicas mediante ultralectura de codón de terminación |
US20130045492A1 (en) | 2010-02-08 | 2013-02-21 | Regeneron Pharmaceuticals, Inc. | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
SI3095871T1 (sl) | 2010-02-08 | 2019-06-28 | Regeneron Pharmaceuticals, Inc. | Miš z navadno lahko verigo |
US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
AU2011279073B2 (en) | 2010-07-16 | 2016-06-09 | Adimab, Llc | Antibody libraries |
EP2644698B1 (fr) | 2010-11-17 | 2018-01-03 | Chugai Seiyaku Kabushiki Kaisha | Molécule de liaison à un antigène multi-spécifique ayant une fonction alternative par rapport à la fonction du facteur viii de coagulation sanguine |
RU2663123C2 (ru) | 2010-11-30 | 2018-08-01 | Чугаи Сейяку Кабусики Кайся | Индуцирующий цитотоксичность терапевтический агент |
RS61946B1 (sr) | 2011-08-05 | 2021-07-30 | Regeneron Pharma | Humanizovani miševi univerzalnog lakog lakca |
EP2883449B1 (fr) | 2012-03-16 | 2018-02-07 | Regeneron Pharmaceuticals, Inc. | Anticorps à chaînes légères modifiés avec de l'histidine et rongeurs génétiquement modifiés pour générer ces anticorps |
US9301510B2 (en) | 2012-03-16 | 2016-04-05 | Regeneron Pharmaceuticals, Inc. | Mice that produce antigen-binding proteins with pH-dependent binding characteristics |
BR112014022855A2 (pt) | 2012-03-16 | 2017-07-18 | Regeneron Pharma | animal não humano geneticamente modificado, mamífero geneticamente modificado, e, método para fabricar um animal não humano |
US20140013456A1 (en) | 2012-03-16 | 2014-01-09 | Regeneron Pharmaceuticals, Inc. | Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same |
CN104583239B (zh) * | 2012-05-10 | 2018-09-18 | 生物蛋白有限公司 | 多特异单克隆抗体 |
RU2758952C1 (ru) | 2013-09-27 | 2021-11-03 | Чугаи Сейяку Кабусики Кайся | Способ получения полипептидного гетеромультимера |
MX2016003617A (es) | 2013-09-30 | 2016-07-21 | Chugai Pharmaceutical Co Ltd | Metodo para producir molecula de enlace al antigeno usando fago auxiliar modificado. |
US10881085B2 (en) | 2014-03-21 | 2021-01-05 | Regeneron Pharmaceuticals, Inc. | Non-human animals that make single domain binding proteins |
EP3126384B1 (fr) * | 2014-04-01 | 2020-12-02 | Adimab, LLC | Analogues d'anticorps multispécifiques comprenant une chaîne légère commune, et leur procédés de préparation et leur utilisation |
WO2015175639A1 (fr) | 2014-05-13 | 2015-11-19 | The Trustees Of The University Of Pennsylvania | Compositions comprenant un virus adéno-associé exprimant des constructions à double anticorps et leurs utilisations |
TWI701435B (zh) | 2014-09-26 | 2020-08-11 | 日商中外製藥股份有限公司 | 測定fviii的反應性之方法 |
MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
TWI700300B (zh) | 2014-09-26 | 2020-08-01 | 日商中外製藥股份有限公司 | 中和具有第viii凝血因子(fviii)機能替代活性的物質之抗體 |
EP3271403A1 (fr) | 2015-03-19 | 2018-01-24 | Regeneron Pharmaceuticals, Inc. | Animaux non humains qui sélectionnent des régions variables de chaînes légères qui se lient à l'antigène |
WO2016159213A1 (fr) | 2015-04-01 | 2016-10-06 | 中外製薬株式会社 | Procédé pour la production d'un hétéro-oligomère polypeptidique |
EP3378488A4 (fr) | 2015-11-18 | 2019-10-30 | Chugai Seiyaku Kabushiki Kaisha | Procédé pour renforcer la réponse immunitaire humorale |
WO2017086367A1 (fr) | 2015-11-18 | 2017-05-26 | 中外製薬株式会社 | Polythérapie utilisant une molécule de liaison à l'antigène à rôle de redirection des cellules t, ciblant des cellules immunosupressives |
KR20180091918A (ko) | 2015-12-28 | 2018-08-16 | 추가이 세이야쿠 가부시키가이샤 | Fc 영역 함유 폴리펩타이드의 정제를 효율화하기 위한 방법 |
CA3016424A1 (fr) | 2016-03-14 | 2017-09-21 | Chugai Seiyaku Kabushiki Kaisha | Medicament therapeutique induisant des lesions cellulaires a utiliser dans le traitement du cancer |
MX2019002510A (es) | 2016-09-06 | 2019-06-24 | Chugai Pharmaceutical Co Ltd | Metodos para usar un anticuerpo biespecifico que reconoce el factor de coagulacion ix y/o el factor de coagulacion ix activado y el factor de coagulacion x y/o factor de coagulacion x activado. |
KR20200041897A (ko) | 2017-08-01 | 2020-04-22 | 에이비 스튜디오 인코포레이티드 | 이중특이 항체 및 그의 용도 |
CA3071236A1 (fr) | 2017-09-29 | 2019-04-04 | Chugai Seiyaku Kabushiki Kaisha | Molecule multispecifique de liaison a l'antigene ayant une activite de substitution de la fonction de cofacteur du facteur viii de coagulation sanguine (fviii), et formulation pharmaceutique contenant ladite molecule en tant que principe actif |
JP7314146B2 (ja) | 2017-12-28 | 2023-07-25 | 中外製薬株式会社 | 細胞傷害誘導治療剤 |
EP3561703B1 (fr) * | 2018-04-25 | 2021-01-20 | Bayer AG | Identification d'appariement de domaines variables des chaînes légères et lourdes d'anticorps |
WO2019244973A1 (fr) | 2018-06-20 | 2019-12-26 | 中外製薬株式会社 | Procédé d'activation de la réponse immunitaire d'une cellule cible et composition associée |
WO2020205504A1 (fr) * | 2019-03-29 | 2020-10-08 | Compass Therapeutics Llc | Chaînes légères communes et leurs procédés d'utilisation |
AU2020288499A1 (en) | 2019-06-05 | 2022-01-27 | Chugai Seiyaku Kabushiki Kaisha | Antibody cleavage site-binding molecule |
JP2023106635A (ja) | 2020-04-17 | 2023-08-02 | 中外製薬株式会社 | 二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法 |
AU2021317974A1 (en) | 2020-07-31 | 2023-03-16 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical Composition comprising Cell Expressing Chimeric Receptor |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9015198D0 (en) * | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
DE69636015T2 (de) | 1995-05-03 | 2007-01-04 | Bioenhancementsments Ltd. | Bispezifische antikörper in denen die bindungsfähigkeit durch eine mittels licht spaltbare gruppe reversibel inhibiert wird |
ES2246069T3 (es) | 1997-05-02 | 2006-02-01 | Genentech, Inc. | Procedimiento de preparacion de anticuerpos multiespecificos que tienen componentes comunes y multimericos. |
DE19819846B4 (de) | 1998-05-05 | 2016-11-24 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Multivalente Antikörper-Konstrukte |
US6897044B1 (en) | 1999-01-28 | 2005-05-24 | Biogen Idec, Inc. | Production of tetravalent antibodies |
EP1238080A2 (fr) | 1999-12-14 | 2002-09-11 | The Burnham Institute | Polypeptides bcl-g, acides nucleique de codage et leurs procedes d'utilisation |
EP1265914B1 (fr) | 2000-03-22 | 2007-12-26 | Curagen Corporation | Nouveaux polypeptides et acides nucleiques codant ces polypeptides |
JP4368196B2 (ja) * | 2000-11-17 | 2009-11-18 | ユニバーシティー オブ ロチェスター | 真核細胞において免疫グロブリン分子を製造および同定するインビトロにおける方法 |
EP1399484B1 (fr) * | 2001-06-28 | 2010-08-11 | Domantis Limited | Ligand a double specificite et son utilisation |
WO2003087163A1 (fr) | 2002-04-15 | 2003-10-23 | Chugai Seiyaku Kabushiki Kaisha | Procede d'elaboration d'une banque scdb |
CA2872136C (fr) * | 2002-07-18 | 2017-06-20 | Merus B.V. | Production par recombinaison de melanges d'anticorps |
JP4794301B2 (ja) | 2003-06-11 | 2011-10-19 | 中外製薬株式会社 | 抗体の製造方法 |
-
2004
- 2004-01-21 DE DE602004021095T patent/DE602004021095D1/de not_active Expired - Lifetime
- 2004-01-21 AT AT04703920T patent/ATE431423T1/de not_active IP Right Cessation
- 2004-01-21 EP EP04703920A patent/EP1605058B1/fr not_active Expired - Lifetime
- 2004-01-21 JP JP2005508106A patent/JP4477579B2/ja not_active Expired - Lifetime
- 2004-01-21 US US10/542,839 patent/US8337841B2/en not_active Expired - Lifetime
- 2004-01-21 WO PCT/JP2004/000496 patent/WO2004065611A1/fr active Application Filing
Also Published As
Publication number | Publication date |
---|---|
EP1605058A1 (fr) | 2005-12-14 |
US20060159673A1 (en) | 2006-07-20 |
EP1605058B1 (fr) | 2009-05-13 |
WO2004065611A1 (fr) | 2004-08-05 |
US8337841B2 (en) | 2012-12-25 |
ATE431423T1 (de) | 2009-05-15 |
JPWO2004065611A1 (ja) | 2006-05-18 |
EP1605058A4 (fr) | 2006-04-19 |
JP4477579B2 (ja) | 2010-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE431423T1 (de) | Verfahren zum screening der leichten kette eines antikörpers | |
MX2009013327A (es) | Ingenieria basada en secuencias y optimizacion de anticuerpos de cadena simple. | |
EP3202786A3 (fr) | Ingénierie et optimisation basées sur la séquence d'anticorps à une seule chaîne | |
NO20052181D0 (no) | Fremgangsmate og apparat for a posisjonere et sentrum for en seismisk kilde | |
JP2013235610A5 (fr) | ||
AR095980A1 (es) | Anticuerpos biespecíficos específicos para fap (proteína de activación fibroblástica) y dr5 (receptor de muerte 5), anticuerpos específicos para dr5 y métodos de utilización | |
NO20061786L (no) | Fremgangsmate for 3D forutsigelse av fri-overflate-multipler | |
ATE408684T1 (de) | Verfahren zur verbesserung von t-zellrezeptoren | |
DK1716181T3 (da) | CDR-reparerede antistoffer | |
WO2005072112A3 (fr) | Methodes de production et d'identification d'anticorps multispecifiques | |
CY1111966T1 (el) | Αντισωματα που δεσμευονται με κυτταροσυνδετο ca 125/0722ρ και μεθοδοι χρησεις αυτων | |
DK1054018T3 (da) | Fab-fragmentbiblioteker og fremgangsmåde til anvendelse deraf | |
DE602006020904D1 (de) | Verfahren zum testen von antigen | |
DE602006021324D1 (de) | Verfahren zur herstellung stabiler b-lymphozyten | |
ATE445645T1 (de) | Verfahren zur selektion von anti-angiogenese antikörperfragmenten | |
DE60130211D1 (de) | Matrix-screening-verfahren | |
WO2008052108A3 (fr) | Procédés d'adaptation d'anticorps monoclonaux à l'être humain | |
WO2010036851A3 (fr) | Conception d'une banque d'anticorps simple chaîne | |
WO2008081331A3 (fr) | Amélioration du niveau d'expression d'anticorps par réingénierie de cadre | |
IL164625A (en) | Method for producing a plurality of monoclonal antibodies and method for identifying a plurality of monoclonal antibodies | |
WO2005049652A3 (fr) | Procede de generation in vitro d'une diversite d'anticorps | |
DE50313529D1 (de) | Verfahren und computer zur planung von versuchen | |
ATE432469T1 (de) | Auf immunreaktion gegen boris basierendes verfahren für den nachweis von krebs | |
ATE331038T1 (de) | Verbessertes verfahren für reverses n-hybrid- screening | |
DE602005021875D1 (de) | Nachweisverfahren für einen liganden der selektiv eine funktionelle kaskade modulieren kann und ein target impliziert sowie dessen verwendung für hochdurchsatz-screening von molekülen die von interesse sind |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |